AC
GCVRZ

Alexandria Capital’s Sanofi Contingent Value Rights GCVRZ Stock Holding History

Alexandria Capital’s Portfolio GCVRZ Stock Details GCVRZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-400
Closed – – 684
2016
Q4 		$0 Hold
400
– – ﹤0.01% 659
2016
Q3 		$0 Hold
400
– – ﹤0.01% 683
2016
Q2 		$0 Hold
400
– – ﹤0.01% 695
2016
Q1 		$0 Hold
400
– – ﹤0.01% 706
2015
Q4 		$0 Buy
+400
New +$56 ﹤0.01% 698

Other funds holding GCVRZ

SCM
Stonehill Capital Management New York $197M AUM 96.45% 1-Year Est. Return
EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
MCM
Mason Capital Management New York $613M AUM 21.43% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
GCM
Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return
MFP
Michael F. Price $846M AUM 0.07% 1-Year Est. Return

Alexandria Capital's GCVRZ Position: Q1 2017 in Review

Alexandria Capital sold out of Sanofi Contingent Value Rights (GCVRZ) in Q1 2017, closing a stake of 400 shares.

Alexandria Capital first reported a position in GCVRZ in Q4 2015 and held it in 5 quarters. The position peaked at $0 in Q4 2016. 111 funds tracked by Wall St. Rank hold GCVRZ as of Q1 2017.

  • Alexandria Capital reported no remaining Sanofi Contingent Value Rights position as of Q1 2017 after selling out during the quarter.
  • Alexandria Capital sold 400 Sanofi Contingent Value Rights shares in Q1 2017.
  • Alexandria Capital first reported a position in Sanofi Contingent Value Rights in Q4 2015 and held it in 5 quarters.
  • Alexandria Capital's Sanofi Contingent Value Rights position peaked at $0 in Q4 2016.
  • 111 funds tracked by Wall St. Rank held Sanofi Contingent Value Rights as of Q1 2017.

Based on Alexandria Capital's 13F filing for Q1 2017, filed 25 Apr 2017.